Netherlands Biotechnology & Medical Research

ProQR Therapeutics NV (PRQR)

Track

Track

Over the past 90 days, ProQR Therapeutics NV insiders have executed six buy transactions totaling approximately $1.7 million. CEO Daniel Anton de Boer and Bart Filius were the primary participants, with no recorded sales. These acquisitions occurred while the stock price remained near the lower end of its 52-week range, preceding the next scheduled results financiers.
Ticker: PRQR Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for ProQR Therapeutics NV. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
de Boer Daniel Anton Chief Executive Officer Executive Director
Transaction date
Purchase
Price
260.65
Quantity 49,249 +3.7%
Value US$4,283,441
de Boer Daniel Anton Chief Executive Officer Executive Director
Transaction date
Purchase
Price
391.00
Quantity 74,457 +19.1%
Value US$2,018,246
Filius Bart Non-Executive Director
Transaction date
Purchase
Price
74.82
Quantity 82,558 -28.1%
Value US$1,573,913
de Boer Daniel Anton Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.74
Quantity 150,000 +100.0%
Value US$261,000
de Boer Daniel Anton Chief Executive Officer Executive Director
Transaction date
Purchase
Price
1.59
Quantity 150,000 +inf%
Value US$238,500
Filius Bart Non-Executive Director
Transaction date
Purchase
Price
1.54
Quantity 150,000 +inf%
Value US$231,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-03 2026-07-31 B Purchase
de Boer Daniel Anton

Chief Executive Officer

Executive Director
49,249 +3.7%
260.65
US$4,283,441 		49,249 +3.7% 260.65 US$4,283,441
2026-08-03 2026-07-31 B Purchase
de Boer Daniel Anton

Chief Executive Officer

Executive Director
74,457 +19.1%
391.00
US$2,018,246 		74,457 +19.1% 391.00 US$2,018,246
2026-07-21 2026-07-17 B Purchase
Filius Bart
Non-Executive Director
82,558 -28.1%
74.82
US$1,573,913 		82,558 -28.1% 74.82 US$1,573,913
2026-07-13 2026-07-09 B Purchase
de Boer Daniel Anton

Chief Executive Officer

Executive Director
150,000 +100.0%
1.74
US$261,000 		150,000 +100.0% 1.74 US$261,000
2026-07-08 2026-07-07 B Purchase
de Boer Daniel Anton

Chief Executive Officer

Executive Director
150,000 +inf%
1.59
US$238,500 		150,000 +inf% 1.59 US$238,500
2026-06-30 2026-06-26 B Purchase
Filius Bart
Non-Executive Director
150,000 +inf%
1.54
US$231,000 		150,000 +inf% 1.54 US$231,000
Explore more

More insider trading research around ProQR Therapeutics NV

More insider trades in Netherlands
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in Europe